<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082380</url>
  </required_header>
  <id_info>
    <org_study_id>A8081009</org_study_id>
    <nct_id>NCT01082380</nct_id>
  </id_info>
  <brief_title>Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers</brief_title>
  <official_title>A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism And Excretion Of [14C]PF-02341066 In Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale for this study is to investigate the absorption, metabolism and excretion of
      [14C]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any
      metabolites, if possible, of [14C]PF 02341066 in humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours (hrs), 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Area under the concentration time-curve from zero to the last measured plasma concentration (AUClast).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half Life (t1/2)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Plasma Decay half-life is the time measured for the concentration to decrease by one half.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of Plasma PF-02341066</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (V/F) in Plasma</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLr) of PF-02341066</measure>
    <time_frame>Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>CLr is the volume of plasma from which a substance is completely removed by the kidney in a given amount of time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to Infinite Time (Ae)</measure>
    <time_frame>Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Ae = concentration of unchanged drug excreted in the urine multiplied by volume of unchanged drug excreted in urine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Amount of Unchanged Drug Excreted in the Urine Expressed as Percent of Dose From Time Zero to Infinite Time [Ae(%)]</measure>
    <time_frame>Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration in Plasma Radioactivity (Cmax)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Radioactivity Concentration (Tmax)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Plasma Radioactivity Concentration (AUClast)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Area under the concentration time-curve from zero to the last measured plasma concentration. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Radioactivity Concentration Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Area under the concentration curve from time zero to extrapolated infinite time [AUC (0 - ∞)] in plasma. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decay Half Life (t1/2) of Radioactivity in Plasma</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma radioactivity concentration to decrease by one half. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of Plasma Radioactivity</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (V/F) in Plasma Radioactivity</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration of Radioactivity in Whole Blood (Cmax)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) of Radioactivity in Whole Blood</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Time to Reach Maximum Observed Concentration (Tmax) of Radioactivity in whole blood. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Radioactivity in Whole Blood</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Area under the concentration time-curve from zero to the last measured concentration (AUClast) in whole blood. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Radioactivity in Whole Blood</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Area under the concentration curve from time zero to extrapolated infinite time [AUC (0 - ∞)] in whole blood. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decay Half-life (t1/2) of Radioactivity in Whole Blood</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Decay half life (t1/2) is the time measured for the concentration to decrease by one half in whole blood. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance of Radioactivity From Whole Blood (CL/F)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution of Radioactivity in Whole Blood (V/F)</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total [14C] Data in Urine</measure>
    <time_frame>Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Cumulative amount excreted in urine at specified intervals after administration of a single 250-mg (100 μCi) oral dose of [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total [14C] Data in Feces</measure>
    <time_frame>From Day 0 through pre-dose (Day1) and as passed through until up to 480 hrs post-dose</time_frame>
    <description>Cumulative amount excreted in feces at specified intervals after administration of a single 250-mg (100 μCi) oral dose of [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Cumulative Percent Recovery of Radioactivity</measure>
    <time_frame>Pre-dose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose for urine and Day 0 through pre-dose (Day1) and as passed through until up to 480 hrs post-dose for feces</time_frame>
    <description>Overall cumulative percent of radioactive dose recovered in urine, feces and toilet tissue at specified intervals after administration of a single 250-mg (100 μCi) oral dose of [14C]PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification and Profiling of Metabolites of [14C]PF-02341066 in Plasma</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>Identification was done by Radio-High Performance liquid chromatography (HPLC) chromatogram. Relative abundance (profiling) of metabolites in chromatogram were determined by dividing sum of radioactive content of fractions contributing to particular peak by sum of radioactive content of all fractions constructing the radio chromatogram. Metabolites accounting for an average of greater than or equal to (&gt;=) 10% of total recoverable radioactivity in plasma were summarized. Radioactivity corresponds to 100 μCi [14C] PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification and Profiling of Metabolites of [14C]PF-02341066 in Feces</measure>
    <time_frame>From Day 0 through pre-dose (Day1) and as passed through until up to 480 hrs post-dose</time_frame>
    <description>In feces, metabolite abundance (profiling) was calculated by multiplying the fractional contribution of radioactive response for the peak in the Radio-HPLC chromatogram to the total radioactivity detected by the percent of administered dose recovered in the matrix. Only those metabolites that were a component of a chromatographic peak that accounted for an average of &gt;=1% of the administered dose, were summarized. Radioactivity corresponds to 100 μCi [14C] PF-02341066.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification and Profiling of Metabolites of [14C]PF-02341066 in Urine</measure>
    <time_frame>Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose</time_frame>
    <description>In urine, metabolite abundance (profiling) was calculated by multiplying the fractional contribution of radioactive response for the peak in the Radio-HPLC chromatogram to the total radioactivity detected by the percent of administered dose recovered in the matrix. Only those metabolites that were a component of a chromatographic peak that accounted for an average of &gt;=1% of the administered dose, were summarized. Radioactivity corresponds to 100 μCi [14C] PF-02341066.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-02341066</intervention_name>
    <description>oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of [14C]PF 02341066</description>
    <arm_group_label>1</arm_group_label>
    <other_name>crizotinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between the ages of 18 and 55 years, inclusive (Healthy is
             defined as no clinically relevant abnormalities identified by a detailed medical
             history, full physical examination, including blood pressure and pulse rate
             measurement, 12 lead ECG and clinical laboratory tests).

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m^2; and a total body weight &gt;50 kg (110
             lbs).

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  Any condition possibly affecting drug absorption (eg, gastrectomy).

          -  A positive urine drug screen.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8081009&amp;StudyName=Radiolabeled%20%5B14C%5DPF-02341066%20Study%20To%20Investigate%20The%20Absorption%2C%20Metabolism%20And%20Excretion%20In%20Healthy%20Male%20Volunteers%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2010</study_first_submitted>
  <study_first_submitted_qc>March 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2010</study_first_posted>
  <results_first_submitted>September 12, 2011</results_first_submitted>
  <results_first_submitted_qc>September 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 26, 2011</results_first_posted>
  <last_update_submitted>February 28, 2012</last_update_submitted>
  <last_update_submitted_qc>February 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiolabeled</keyword>
  <keyword>healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PF-02341066 250 mg</title>
          <description>Single oral dose of PF-02341066 250 milligram (mg) containing 100 micro-curie (μCi) Carbon -14[14C].</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PF-02341066 250 mg</title>
          <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.2" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours (hrs), 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The Pharmacokinetic (PK) parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <population>The Pharmacokinetic (PK) parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.400" spread="54.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" lower_limit="1.98" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast)</title>
        <description>Area under the concentration time-curve from zero to the last measured plasma concentration (AUClast).</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast)</title>
          <description>Area under the concentration time-curve from zero to the last measured plasma concentration (AUClast).</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2686.0" spread="1119.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]</title>
        <description>AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]</title>
          <description>AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2777.0" spread="1114.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Decay Half Life (t1/2)</title>
        <description>Plasma Decay half-life is the time measured for the concentration to decrease by one half.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Decay Half Life (t1/2)</title>
          <description>Plasma Decay half-life is the time measured for the concentration to decrease by one half.</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.970" spread="13.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Oral Clearance (CL/F) of Plasma PF-02341066</title>
        <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F) of Plasma PF-02341066</title>
          <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.140" spread="23.984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (V/F) in Plasma</title>
        <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (V/F) in Plasma</title>
          <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed.</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12110.0" spread="4544.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance (CLr) of PF-02341066</title>
        <description>CLr is the volume of plasma from which a substance is completely removed by the kidney in a given amount of time.</description>
        <time_frame>Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CLr) of PF-02341066</title>
          <description>CLr is the volume of plasma from which a substance is completely removed by the kidney in a given amount of time.</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to Infinite Time (Ae)</title>
        <description>Ae = concentration of unchanged drug excreted in the urine multiplied by volume of unchanged drug excreted in urine.</description>
        <time_frame>Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to Infinite Time (Ae)</title>
          <description>Ae = concentration of unchanged drug excreted in the urine multiplied by volume of unchanged drug excreted in urine.</description>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
          <units>mg</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.847" spread="3.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Amount of Unchanged Drug Excreted in the Urine Expressed as Percent of Dose From Time Zero to Infinite Time [Ae(%)]</title>
        <time_frame>Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Unchanged Drug Excreted in the Urine Expressed as Percent of Dose From Time Zero to Infinite Time [Ae(%)]</title>
          <population>The PK parameter analysis population included all treated participants who had at least 1 of the PK parameters of primary interest.</population>
          <units>Percent dose of unchanged drug</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.339" spread="1.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration in Plasma Radioactivity (Cmax)</title>
        <description>Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration in Plasma Radioactivity (Cmax)</title>
          <description>Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
          <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
          <units>nanogram-equivalent/milliliter(ng-eq/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="435.600" spread="82.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Radioactivity Concentration (Tmax)</title>
        <description>Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Radioactivity Concentration (Tmax)</title>
          <description>Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
          <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="2.98" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Plasma Radioactivity Concentration (AUClast)</title>
        <description>Area under the concentration time-curve from zero to the last measured plasma concentration. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Plasma Radioactivity Concentration (AUClast)</title>
          <description>Area under the concentration time-curve from zero to the last measured plasma concentration. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
          <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
          <units>ng-eq*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22830.0" spread="2636.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Radioactivity Concentration Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]</title>
        <description>Area under the concentration curve from time zero to extrapolated infinite time [AUC (0 - ∞)] in plasma. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Radioactivity Concentration Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]</title>
          <description>Area under the concentration curve from time zero to extrapolated infinite time [AUC (0 - ∞)] in plasma. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
          <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
          <units>ng-eq*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Decay Half Life (t1/2) of Radioactivity in Plasma</title>
        <description>Plasma decay half-life is the time measured for the plasma radioactivity concentration to decrease by one half. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Decay Half Life (t1/2) of Radioactivity in Plasma</title>
          <description>Plasma decay half-life is the time measured for the plasma radioactivity concentration to decrease by one half. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
          <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Oral Clearance (CL/F) of Plasma Radioactivity</title>
        <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F) of Plasma Radioactivity</title>
          <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
          <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (V/F) in Plasma Radioactivity</title>
        <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (V/F) in Plasma Radioactivity</title>
          <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
          <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration of Radioactivity in Whole Blood (Cmax)</title>
        <description>Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration of Radioactivity in Whole Blood (Cmax)</title>
          <description>Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
          <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
          <units>ng-eq/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312.300" spread="62.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Concentration (Tmax) of Radioactivity in Whole Blood</title>
        <description>Time to Reach Maximum Observed Concentration (Tmax) of Radioactivity in whole blood. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Concentration (Tmax) of Radioactivity in Whole Blood</title>
          <description>Time to Reach Maximum Observed Concentration (Tmax) of Radioactivity in whole blood. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
          <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="2.98" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Radioactivity in Whole Blood</title>
        <description>Area under the concentration time-curve from zero to the last measured concentration (AUClast) in whole blood. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Radioactivity in Whole Blood</title>
          <description>Area under the concentration time-curve from zero to the last measured concentration (AUClast) in whole blood. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
          <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
          <units>ng-eq*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7032.0" spread="1284.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Radioactivity in Whole Blood</title>
        <description>Area under the concentration curve from time zero to extrapolated infinite time [AUC (0 - ∞)] in whole blood. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Radioactivity in Whole Blood</title>
          <description>Area under the concentration curve from time zero to extrapolated infinite time [AUC (0 - ∞)] in whole blood. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
          <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
          <units>ng-eq*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Decay Half-life (t1/2) of Radioactivity in Whole Blood</title>
        <description>Decay half life (t1/2) is the time measured for the concentration to decrease by one half in whole blood. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Decay Half-life (t1/2) of Radioactivity in Whole Blood</title>
          <description>Decay half life (t1/2) is the time measured for the concentration to decrease by one half in whole blood. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
          <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Oral Clearance of Radioactivity From Whole Blood (CL/F)</title>
        <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance of Radioactivity From Whole Blood (CL/F)</title>
          <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
          <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution of Radioactivity in Whole Blood (V/F)</title>
        <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution of Radioactivity in Whole Blood (V/F)</title>
          <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed. Radioactivity corresponds to 100 μCi [14C]PF-02341066.</description>
          <population>Data was insufficient to analyze as only 2 participants were evaluable for the parameter.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total [14C] Data in Urine</title>
        <description>Cumulative amount excreted in urine at specified intervals after administration of a single 250-mg (100 μCi) oral dose of [14C]PF-02341066.</description>
        <time_frame>Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Total [14C] Data in Urine</title>
          <description>Cumulative amount excreted in urine at specified intervals after administration of a single 250-mg (100 μCi) oral dose of [14C]PF-02341066.</description>
          <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
          <units>ng-eq</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56200000" spread="11500000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total [14C] Data in Feces</title>
        <description>Cumulative amount excreted in feces at specified intervals after administration of a single 250-mg (100 μCi) oral dose of [14C]PF-02341066.</description>
        <time_frame>From Day 0 through pre-dose (Day1) and as passed through until up to 480 hrs post-dose</time_frame>
        <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Total [14C] Data in Feces</title>
          <description>Cumulative amount excreted in feces at specified intervals after administration of a single 250-mg (100 μCi) oral dose of [14C]PF-02341066.</description>
          <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
          <units>ng-eq</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160000000" spread="15000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Cumulative Percent Recovery of Radioactivity</title>
        <description>Overall cumulative percent of radioactive dose recovered in urine, feces and toilet tissue at specified intervals after administration of a single 250-mg (100 μCi) oral dose of [14C]PF-02341066.</description>
        <time_frame>Pre-dose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose for urine and Day 0 through pre-dose (Day1) and as passed through until up to 480 hrs post-dose for feces</time_frame>
        <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Cumulative Percent Recovery of Radioactivity</title>
          <description>Overall cumulative percent of radioactive dose recovered in urine, feces and toilet tissue at specified intervals after administration of a single 250-mg (100 μCi) oral dose of [14C]PF-02341066.</description>
          <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
          <units>Percent recovery of radioactivity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.20" spread="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feces</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.10" spread="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.20" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Identification and Profiling of Metabolites of [14C]PF-02341066 in Plasma</title>
        <description>Identification was done by Radio-High Performance liquid chromatography (HPLC) chromatogram. Relative abundance (profiling) of metabolites in chromatogram were determined by dividing sum of radioactive content of fractions contributing to particular peak by sum of radioactive content of all fractions constructing the radio chromatogram. Metabolites accounting for an average of greater than or equal to (&gt;=) 10% of total recoverable radioactivity in plasma were summarized. Radioactivity corresponds to 100 μCi [14C] PF-02341066.</description>
        <time_frame>Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Identification and Profiling of Metabolites of [14C]PF-02341066 in Plasma</title>
          <description>Identification was done by Radio-High Performance liquid chromatography (HPLC) chromatogram. Relative abundance (profiling) of metabolites in chromatogram were determined by dividing sum of radioactive content of fractions contributing to particular peak by sum of radioactive content of all fractions constructing the radio chromatogram. Metabolites accounting for an average of greater than or equal to (&gt;=) 10% of total recoverable radioactivity in plasma were summarized. Radioactivity corresponds to 100 μCi [14C] PF-02341066.</description>
          <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
          <units>Percentage of recovered radioactivity</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PF-02341066</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10, PF-06260182</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Identification and Profiling of Metabolites of [14C]PF-02341066 in Feces</title>
        <description>In feces, metabolite abundance (profiling) was calculated by multiplying the fractional contribution of radioactive response for the peak in the Radio-HPLC chromatogram to the total radioactivity detected by the percent of administered dose recovered in the matrix. Only those metabolites that were a component of a chromatographic peak that accounted for an average of &gt;=1% of the administered dose, were summarized. Radioactivity corresponds to 100 μCi [14C] PF-02341066.</description>
        <time_frame>From Day 0 through pre-dose (Day1) and as passed through until up to 480 hrs post-dose</time_frame>
        <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Identification and Profiling of Metabolites of [14C]PF-02341066 in Feces</title>
          <description>In feces, metabolite abundance (profiling) was calculated by multiplying the fractional contribution of radioactive response for the peak in the Radio-HPLC chromatogram to the total radioactivity detected by the percent of administered dose recovered in the matrix. Only those metabolites that were a component of a chromatographic peak that accounted for an average of &gt;=1% of the administered dose, were summarized. Radioactivity corresponds to 100 μCi [14C] PF-02341066.</description>
          <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
          <units>Percentage of radioactive dose</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PF-02341066</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was collected but could not be quantified.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Identification and Profiling of Metabolites of [14C]PF-02341066 in Urine</title>
        <description>In urine, metabolite abundance (profiling) was calculated by multiplying the fractional contribution of radioactive response for the peak in the Radio-HPLC chromatogram to the total radioactivity detected by the percent of administered dose recovered in the matrix. Only those metabolites that were a component of a chromatographic peak that accounted for an average of &gt;=1% of the administered dose, were summarized. Radioactivity corresponds to 100 μCi [14C] PF-02341066.</description>
        <time_frame>Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose</time_frame>
        <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-02341066 250 mg</title>
            <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
          </group>
        </group_list>
        <measure>
          <title>Identification and Profiling of Metabolites of [14C]PF-02341066 in Urine</title>
          <description>In urine, metabolite abundance (profiling) was calculated by multiplying the fractional contribution of radioactive response for the peak in the Radio-HPLC chromatogram to the total radioactivity detected by the percent of administered dose recovered in the matrix. Only those metabolites that were a component of a chromatographic peak that accounted for an average of &gt;=1% of the administered dose, were summarized. Radioactivity corresponds to 100 μCi [14C] PF-02341066.</description>
          <population>The radioactivity parameter analysis population included all treated participants who had at least 1 of the radioactivity parameters of primary interest.</population>
          <units>Percentage of radioactive dose</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PF-02341066</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>PF-02341066 250 mg</title>
          <description>Single oral dose of PF-02341066 250 mg containing 100 μCi [14C].</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

